New drug cocktail aims to tackle tough lymphoma
NCT ID NCT07570017
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called rocbrutinib combined with standard chemotherapy (R-GemOx) in 42 people with a type of lymphoma (DLBCL) that has returned or not responded to treatment. The main goals are to find a safe dose and see if the combination shrinks tumors. It is a small, early study focused on safety first.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rocbrutinib (LP-168) combined with rituximab, gemcitabine, and oxaliplatin (R-GemOx)
What this could lead to
If successful, this could point toward a new treatment option for people with a hard-to-treat type of lymphoma that has come back or not responded to prior therapy.
What could go wrong
This is a very early (Phase Ib) trial with only 42 participants, so it is primarily testing safety and dosing. The combination may not prove effective or could cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510050, China